Your browser doesn't support javascript.
loading
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma.
Kazandjian, Dickran; Diamond, Benjamin; Papadimitriou, Marios; Hill, Elizabeth; Sklavenitis-Pistofidis, Romanos; Ziccheddu, Bachisio; Blaney, Patrick; Chojnacka, Monika; Durante, Michael; Maclachlan, Kylee; Young, Ryan; Usmani, Saad; Davies, Faith; Getz, Gad; Ghobrial, Irene; Korde, Neha; Morgan, Gareth; Maura, Francesco; Landgren, Ola.
Afiliación
  • Kazandjian D; Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
  • Diamond B; Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Papadimitriou M; Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
  • Hill E; Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
  • Sklavenitis-Pistofidis R; Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Ziccheddu B; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Blaney P; Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
  • Chojnacka M; Myeloma Research Program, NYU Langone, Perlmutter Cancer Center, New York, New York.
  • Durante M; Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
  • Maclachlan K; Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
  • Young R; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Usmani S; Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Davies F; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Getz G; Myeloma Research Program, NYU Langone, Perlmutter Cancer Center, New York, New York.
  • Ghobrial I; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Korde N; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Morgan G; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Maura F; Myeloma Research Program, NYU Langone, Perlmutter Cancer Center, New York, New York.
  • Landgren O; Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
Clin Cancer Res ; 30(19): 4482-4490, 2024 Oct 01.
Article en En | MEDLINE | ID: mdl-38652812
ABSTRACT

PURPOSE:

Early intervention for high-risk smoldering multiple myeloma (HR-SMM) achieves deep and prolonged responses. It is unclear if beneficial outcomes are due to the treatment of less complex, susceptible disease or inaccuracy in clinical definition of cases entered. EXPERIMENTAL

DESIGN:

In this study, we interrogated whole-genome and whole-exome sequencing for 54 patients across two HR-SMM interventional studies (NCT01572480 and NCT02279394).

RESULTS:

We reveal that the genomic landscape of treated HR-SMM is generally simple as compared with newly diagnosed multiple myeloma counterparts with less inactivation of tumor suppressor genes, RAS pathway mutations, MYC disruption, and APOBEC contribution. The absence of these events parallels that of indolent precursor conditions, possibly explaining overall excellent outcomes. However, some patients harboring genomic complexity fail to sustain response and experience resistant, progressive disease. Overall, clinical risk scores do not effectively discriminate between genomically indolent and aggressive disease.

CONCLUSIONS:

Genomic profiling can contextualize the advantage of early intervention in SMM and guide personalization of therapy. See related commentary by Weinhold and Rasche, p. 4263.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Genómica / Mieloma Múltiple Quiescente / Mutación Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res / Clin. cancer res / Clinical cancer research Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Genómica / Mieloma Múltiple Quiescente / Mutación Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res / Clin. cancer res / Clinical cancer research Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article